- Report
- November 2021
- 261 Pages
Global
From €2351EUR$2,625USD£2,046GBP
€4701EUR$5,250USD£4,091GBP
- Report
- June 2023
- 186 Pages
Global
From €4164EUR$4,650USD£3,624GBP
- Report
- March 2023
- 150 Pages
Global
From €5328EUR$5,950USD£4,637GBP
- Report
- September 2023
- 190 Pages
Global
From €2230EUR$2,490USD£1,941GBP
- Report
- March 2023
- 356 Pages
Global
From €4477EUR$5,000USD£3,897GBP
- Report
- January 2025
- 85 Pages
Saudi Arabia
From €3134EUR$3,500USD£2,728GBP
- Report
- March 2024
- 200 Pages
Global
From €3716EUR$4,150USD£3,234GBP
- Report
- January 2024
- 200 Pages
Global
From €3716EUR$4,150USD£3,234GBP
- Report
- August 2024
- 150 Pages
Global
From €3447EUR$3,850USD£3,000GBP
€4343EUR$4,850USD£3,780GBP
- Report
- June 2022
- 242 Pages
Global
From €3224EUR$3,600USD£2,806GBP
- Book
- January 2016
- 368 Pages
- Book
- September 2023
North America
Kidney cancer, also known as renal cancer, is a type of cancer that originates in the kidneys. It is one of the most common types of cancer in adults, and is typically diagnosed in individuals over the age of 50. Symptoms of kidney cancer can include blood in the urine, pain in the side or lower back, and a lump in the abdomen. Treatment options for kidney cancer include surgery, radiation therapy, and chemotherapy.
In the oncology market, kidney cancer is a major area of focus for drug development. Pharmaceutical companies are researching and developing new treatments to improve outcomes for patients with kidney cancer. These treatments include targeted therapies, immunotherapies, and combination therapies.
Some companies in the kidney cancer market include Bristol-Myers Squibb, Merck, Pfizer, AstraZeneca, and Novartis. Show Less Read more
